Fetal Appendage Mesenchymal Stem Cell Selection for High Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amniotic mesenchymal stem cells exhibit low proliferative properties, making large-scale and rapid production challenging, and existing methods do not effectively select for highly proliferative cells or maintain their high proliferative capacity during culture.
Innovation Solution
A cell population comprising mesenchymal stem cells from the fetal appendage is cultured to maintain a proportion of CD105+ cells at 50% or more and CD106+ cells less than 5%, with CD200+ cells less than 10%, allowing for the production of highly proliferative cells and optimizing enzyme treatment conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional culture methods are used for amniotic mesenchymal stem cells, then the cells can be maintained in culture, but the proliferative capacity is low and population doubling level does not increase after 3 passages
Solution Approach 1:
The patent changes the culture parameters by controlling the proportion of CD105+ cells (50% or more) and CD200+ cells (less than 10%) in the cell population. This parameter control enables highly proliferative cells to be obtained and maintained in culture without the proliferation arrest that occurs in conventional methods after 3 passages.
2Quantity of substance
If conventional culture methods are used, then cells can be cultured, but large-scale and rapid production is difficult
Solution Approach 1:
By controlling the marker expression proportions (CD105+ ≥50%, CD200+ <10%), the patent enables large-scale and rapid cell production. The highly proliferative cells can be expanded quickly to achieve the required cell quantities for cell therapy applications.
3Stability of the object's composition
If conventional culture methods are used, then cells can be maintained, but high proliferative capacity cannot be maintained during culture
Solution Approach 1:
The patent uses flow cytometry to monitor the proportion of CD105+ and CD200+ cells in the culture, providing feedback on the proliferative state. This allows for maintenance of high proliferative capacity by ensuring the cell population meets the specified marker proportions throughout the culture process.
4Manufacturing precision
If cell population is not selected, then all cells can be cultured, but highly proliferative cells cannot be selectively prepared
Solution Approach 1:
The patent establishes specific marker expression thresholds (CD105+ ≥50%, CD200+ <10%) as selection criteria. This parameter-based selection method enables precise identification and preparation of highly proliferative cells without requiring complex selection processes.
Data Source
AI summary
An object of the present invention is to provide highly proliferative mesenchymal stem cells (MSCs) useful for the large-scale and rapid production of a cell preparation, and a cell population comprising the mesenchymal stem cells. According to the present invention, there is provided a cell population comprising mesenchymal stem cells derived from the fetal appendage, wherein, in the cell population, the proportion of CD105+ mesenchymal stem cells is 50% or more, the proportion of CD200+ mesenchymal stem cells is less than 10%, and the proportion of CD106+ mesenchymal stem cells is less than 5%.